Chris Zellner

Chris Zellner is a co-founder of Asymmetry Capital Management, a San Francisco–based global healthcare long/short equity hedge fund he helped launch alongside founder and CIO Scott Kay. Zellner joined the firm in 2012 (the funds launched in January 2013) and serves as its Founder, Chief Operating Officer, and Chief Compliance Officer — the partner responsible for the operational, financial, regulatory, and investor-relations/business-development side of the business, freeing Kay to focus on investing. The firm was designed to deliver risk-adjusted returns through a diversified global portfolio of healthcare securities, typically running 45–55 positions with roughly $94 million in assets at the time it was profiled.

Zellner brings more than 25 years of financial-services experience across a series of major Wall Street institutions, including the New York Stock Exchange (NYSE), Morgan Stanley, Lehman Brothers, Merrill Lynch, and Bank of America Merrill Lynch. His background spans Prime Brokerage, Equity Derivatives, and Equity Capital Markets, and he is credited with developing the NYSE's IPO listing business — an operations-, markets-, and capital-formation-oriented career that complements the investment side of Asymmetry.

He earned both his B.S. and M.B.A. from the Stern School of Business at New York University. Public records list him under the full name Christopher Robert Zellner in connection with Asymmetry Capital Management, L.P. Reporting indicates Asymmetry's funds were wound down around January 2022, though Zellner continues to be associated with the Asymmetry Capital name and email domain.

• Professionally, Zellner's expertise is in healthcare and life-sciences equities, executed as a long/short strategy at Asymmetry (20–30 long positions and 20–25 short positions across healthcare sub-sectors).
• Startup-investor aggregators (e.g., Foundersuite) classify him as an angel investor participating in seed rounds, consistent with the stub data — but no publicly documented thesis statement, check-size range, or target-company criteria for his personal angel activity could be verified.
• Given his career, the most credible fit for direct startup engagement would be healthcare, biotech, medical, and life-sciences-adjacent companies, plus his deep knowledge of capital markets and IPO listings.